| Title : Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin - Herman_2007_Clin.Pharmacol.Ther_81_761 |
| Author(s) : Herman GA , Stein PP , Thornberry NA , Wagner JA |
| Ref : Clinical Pharmacology & Therapeutics , 81 :761 , 2007 |
|
Abstract :
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes. |
| PubMedSearch : Herman_2007_Clin.Pharmacol.Ther_81_761 |
| PubMedID: 17392725 |
| Inhibitor | Sitagliptin |
Herman GA, Stein PP, Thornberry NA, Wagner JA (2007)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin
Clinical Pharmacology & Therapeutics
81 :761
Herman GA, Stein PP, Thornberry NA, Wagner JA (2007)
Clinical Pharmacology & Therapeutics
81 :761